-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $3

Benzinga·11/25/2025 18:14:20
Listen to the news
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $5 to $3.